Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Affimed GmbH is managing 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct art units, indicating that the company's biological research spans multiple specialized examination groups. The involvement of 3 distinct examiners ensures that each of the pending office actions is being evaluated by a different individual.
PRIEST, JESSICA MARIE is the busiest examiner, currently responsible for 1 pending office action. This means that the 3 pending office actions are split among the distinct examiners, with no single examiner managing more than one case. This distribution requires the company to manage three separate examiner relationships simultaneously within the Biotechnology & Pharmaceuticals field.
The 2 distinct art units involved suggest some level of technical clustering for the pending office actions. Practitioners should analyze the distinct art units to identify potential trends in examination behavior that might affect the 3 distinct examiners. Coordinating responses across these different units will be essential for maintaining consistency in the company's pharmaceutical patent strategy. Resolving the 1 pending office action with the busiest examiner will be a critical step for the portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| §112 only | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PRIEST, JESSICA MARIE | 1 | — | — |
| DAHLE, CHUN WU | 1 | 50.2% | +51.2% |
| KIM, YUNSOO | 1 | 65.9% | +34.3% |
| GUSTILO, ESTELLA M | 1 | 53.6% | +34.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18293307 | DUPLEXBODIES | PRIEST, JESSICA MARIE | — |
| 18030628 | TRISPECIFIC BINDERS | DAHLE, CHUN WU | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17807211 | METHOD FOR THE PRODUCTION OF BISPECIFIC FCYRIII X CD30 ANTIBODY CONSTRUCT | KIM, YUNSOO | 3d overdue |
| 18030628 | TRISPECIFIC BINDERS | DAHLE, CHUN WU | — |
| 17177052 | Cryopreserved NK cells preloaded with an antibody construct | GUSTILO, ESTELLA M | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| 1674 | 1 |
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18293307 | DUPLEXBODIES | PRIEST, JESSICA MARIE | — | §103§112 | Non-Final OA | — | Pending | Jan 29, 2024 |
| 18030628 | TRISPECIFIC BINDERS | DAHLE, CHUN WU | 1641 | §102§103§112 | Non-Final OA | — | Pending | Apr 06, 2023 |
| 17807211 | METHOD FOR THE PRODUCTION OF BISPECIFIC FCYRIII X CD30 ANTIBODY CONSTRUCT | KIM, YUNSOO | 1674 | §112 | Final Rejection | 3d overdue | Pending | Jun 16, 2022 |
| 17177052 | Cryopreserved NK cells preloaded with an antibody construct | GUSTILO, ESTELLA M | 1646 | §103Other | Final Rejection | — | Pending | Feb 16, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial